The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...

Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...

Merck (MRK.N), opens new tab said on Monday its experimental endometrial cancer drug met the main goals of a late-stage trial ...

Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or ...

Earlier this week, Merck announced that its pivotal Phase 3 TroFuse-005 trial showed sacituzumab tirumotecan significantly improved overall and progression-free survival versus chemotherapy in certain ...

The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.

Shakeya Allen was 27 years old when she felt something was not right with her health. A miscarriage would lead to her diagnosis. “They said, ‘Don’t worry. Women under 40 do not get uterine cancer.

In January, the American Cancer Society reported that for the first time women younger than 50 had a higher cancer incidence rate than men. Based on 2023 data, cancer incidence rates among women under ...

The most common type of gynecologic cancer in the U.S. has been on the rise in recent years — and there’s no standard screening for it. Uterine cancer will affect about 66,200 women in 2023 in the U.S ...

Endometrial cancer, also known as uterine cancer, is the most common cancer of the female reproductive system. It begins in the lining of the uterus, called the endometrium. While it usually affects ...